188 related articles for article (PubMed ID: 37656238)
1. Cardiac fibroblast GSK-3α aggravates ischemic cardiac injury by promoting fibrosis, inflammation, and impairing angiogenesis.
Umbarkar P; Ejantkar S; Ruiz Ramirez SY; Toro Cora A; Zhang Q; Tousif S; Lal H
Basic Res Cardiol; 2023 Sep; 118(1):35. PubMed ID: 37656238
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast GSK-3α Promotes Fibrosis via RAF-MEK-ERK Pathway in the Injured Heart.
Umbarkar P; Tousif S; Singh AP; Anderson JC; Zhang Q; Tallquist MD; Woodgett J; Lal H
Circ Res; 2022 Sep; 131(7):620-636. PubMed ID: 36052698
[TBL] [Abstract][Full Text] [Related]
3. Glycogen synthase kinase-3α limits ischemic injury, cardiac rupture, post-myocardial infarction remodeling and death.
Lal H; Zhou J; Ahmad F; Zaka R; Vagnozzi RJ; Decaul M; Woodgett J; Gao E; Force T
Circulation; 2012 Jan; 125(1):65-75. PubMed ID: 22086876
[TBL] [Abstract][Full Text] [Related]
4. Cardiac fibroblast glycogen synthase kinase-3β regulates ventricular remodeling and dysfunction in ischemic heart.
Lal H; Ahmad F; Zhou J; Yu JE; Vagnozzi RJ; Guo Y; Yu D; Tsai EJ; Woodgett J; Gao E; Force T
Circulation; 2014 Jul; 130(5):419-30. PubMed ID: 24899689
[TBL] [Abstract][Full Text] [Related]
5. GSK-3α aggravates inflammation, metabolic derangement, and cardiac injury post-ischemia/reperfusion.
Ahmad F; Marzook H; Gupta A; Aref A; Patil K; Khan AA; Saleh MA; Koch WJ; Woodgett JR; Qaisar R
J Mol Med (Berl); 2023 Nov; 101(11):1379-1396. PubMed ID: 37707557
[TBL] [Abstract][Full Text] [Related]
6. Role of GSK-3 in Cardiac Health: Focusing on Cardiac Remodeling and Heart Failure.
Tariq U; Uppulapu SK; Banerjee SK
Curr Drug Targets; 2021; 22(13):1568-1576. PubMed ID: 33655828
[TBL] [Abstract][Full Text] [Related]
7. GSK-3 at the heart of cardiometabolic diseases: Isoform-specific targeting is critical to therapeutic benefit.
Umbarkar P; Ruiz Ramirez SY; Toro Cora A; Tousif S; Lal H
Biochim Biophys Acta Mol Basis Dis; 2023 Aug; 1869(6):166724. PubMed ID: 37094727
[TBL] [Abstract][Full Text] [Related]
8. Cardiomyocyte-specific deletion of Gsk3α mitigates post-myocardial infarction remodeling, contractile dysfunction, and heart failure.
Ahmad F; Lal H; Zhou J; Vagnozzi RJ; Yu JE; Shang X; Woodgett JR; Gao E; Force T
J Am Coll Cardiol; 2014 Aug; 64(7):696-706. PubMed ID: 25125302
[TBL] [Abstract][Full Text] [Related]
9. Glycogen synthase kinase-3alpha reduces cardiac growth and pressure overload-induced cardiac hypertrophy by inhibition of extracellular signal-regulated kinases.
Zhai P; Gao S; Holle E; Yu X; Yatani A; Wagner T; Sadoshima J
J Biol Chem; 2007 Nov; 282(45):33181-91. PubMed ID: 17855351
[TBL] [Abstract][Full Text] [Related]
10. The GSK-3 family as therapeutic target for myocardial diseases.
Lal H; Ahmad F; Woodgett J; Force T
Circ Res; 2015 Jan; 116(1):138-49. PubMed ID: 25552693
[TBL] [Abstract][Full Text] [Related]
11. Constitutive glycogen synthase kinase-3alpha/beta activity protects against chronic beta-adrenergic remodelling of the heart.
Webb IG; Nishino Y; Clark JE; Murdoch C; Walker SJ; Makowski MR; Botnar RM; Redwood SR; Shah AM; Marber MS
Cardiovasc Res; 2010 Aug; 87(3):494-503. PubMed ID: 20299330
[TBL] [Abstract][Full Text] [Related]
12. Glycogen synthase kinase-3beta regulates post-myocardial infarction remodeling and stress-induced cardiomyocyte proliferation in vivo.
Woulfe KC; Gao E; Lal H; Harris D; Fan Q; Vagnozzi R; DeCaul M; Shang X; Patel S; Woodgett JR; Force T; Zhou J
Circ Res; 2010 May; 106(10):1635-45. PubMed ID: 20360256
[TBL] [Abstract][Full Text] [Related]
13. Distinct roles of GSK-3alpha and GSK-3beta phosphorylation in the heart under pressure overload.
Matsuda T; Zhai P; Maejima Y; Hong C; Gao S; Tian B; Goto K; Takagi H; Tamamori-Adachi M; Kitajima S; Sadoshima J
Proc Natl Acad Sci U S A; 2008 Dec; 105(52):20900-5. PubMed ID: 19106302
[TBL] [Abstract][Full Text] [Related]
14. 2,5-Dimethylcelecoxib prevents pressure-induced left ventricular remodeling through GSK-3 activation.
Fujita A; Takahashi-Yanaga F; Morimoto S; Yoshihara T; Arioka M; Igawa K; Tomooka K; Hoka S; Sasaguri T
Hypertens Res; 2017 Feb; 40(2):130-139. PubMed ID: 27628899
[TBL] [Abstract][Full Text] [Related]
15. Myocardial injection with GSK-3β-overexpressing bone marrow-derived mesenchymal stem cells attenuates cardiac dysfunction after myocardial infarction.
Cho J; Zhai P; Maejima Y; Sadoshima J
Circ Res; 2011 Feb; 108(4):478-89. PubMed ID: 21233455
[TBL] [Abstract][Full Text] [Related]
16. Loss of Adult Cardiac Myocyte GSK-3 Leads to Mitotic Catastrophe Resulting in Fatal Dilated Cardiomyopathy.
Zhou J; Ahmad F; Parikh S; Hoffman NE; Rajan S; Verma VK; Song J; Yuan A; Shanmughapriya S; Guo Y; Gao E; Koch W; Woodgett JR; Madesh M; Kishore R; Lal H; Force T
Circ Res; 2016 Apr; 118(8):1208-22. PubMed ID: 26976650
[TBL] [Abstract][Full Text] [Related]
17. Myocardial stress remodelling after regional infarction is independent of glycogen synthase kinase-3 inactivation.
Webb IG; Sicard P; Clark JE; Redwood S; Marber MS
J Mol Cell Cardiol; 2010 Nov; 49(5):897-900. PubMed ID: 20696171
[TBL] [Abstract][Full Text] [Related]
18. Cardiomyocyte-GSK-3α promotes mPTP opening and heart failure in mice with chronic pressure overload.
Ahmad F; Singh AP; Tomar D; Rahmani M; Zhang Q; Woodgett JR; Tilley DG; Lal H; Force T
J Mol Cell Cardiol; 2019 May; 130():65-75. PubMed ID: 30928428
[TBL] [Abstract][Full Text] [Related]
19. Glycogen synthase kinase-3β inhibition alleviates activation of the NLRP3 inflammasome in myocardial infarction.
Wang S; Su X; Xu L; Chang C; Yao Y; Komal S; Cha X; Zang M; Ouyang X; Zhang L; Han S
J Mol Cell Cardiol; 2020 Dec; 149():82-94. PubMed ID: 32991876
[TBL] [Abstract][Full Text] [Related]
20. Cardiomyocyte-GSK-3β deficiency induces cardiac progenitor cell proliferation in the ischemic heart through paracrine mechanisms.
Yusuf AM; Qaisar R; Al-Tamimi AO; Jayakumar MN; Woodgett JR; Koch WJ; Ahmad F
J Cell Physiol; 2022 Mar; 237(3):1804-1817. PubMed ID: 34812500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
